European Radiology:使用增强CT的放射组学在预测结直肠癌患者术后复发方面的应用

2022-02-10 shaosai MedSci原创

结直肠癌(CRC)是全球范围发病率前十的恶性肿瘤之一,由于年龄结构的变化和人口增长,预计未来几十年CRC的发病率将继续增加。

结直肠癌(CRC)全球范围发病率前十的恶性肿瘤之一,由于年龄结构的变化和人口增长,预计未来几十年CRC的发病率将继续增加。

癌症的特点是在肿瘤发展的不同阶段具有明显的肿瘤内遗传异质性,这一特性可以通过放射组学分析在医学图像上进行评估。影像学特征可以作为一种生物指标的替代参数应用于诊断、预后以及与治疗反应相关的基因表达谱系。大多数已建立的放射组学模型均是基于计算机断层扫描(CT)图像,包括不同阶段的CRC,目前还没有基于CT的放射组学模型来预测II期和III期CRC的复发情况。

近日,发表在European Radiology杂志的一项研究评估了使用放射组学定性的对比增强(CE)CT扫描预测作为II期和III期CRC患者复发的价值,CRC患者个性化治疗方案的制定及评估提供了参考依据

项研究纳入了193名在在2008年7月1日至2017年3月15日期间在法国两个不同的大学医院被诊断为II期和III期结直肠腺癌的患者。采用了统计学协调方法Bootstrapped ComBat(B-ComBat)平衡了两个中心数据的差异性使用3种不同的机器学习(ML)建立的预测无病生存(DFS)模型。(1)多变量回归(MR),在基于最小绝对收缩和选择算子(LASSO)的特征选择后进行10倍交叉验证,(2)随机森林(RF)和(3)支持向量机(SVM),两者都有嵌入式特征选择。 

与使用未经转换的原始数据相比,经过我们提出的B-ComBat协调后,平衡模型和95%敏感性模型的性能都系统地提高了。将一个临床变量(术后化疗)与两个放射组学形状描述符(紧凑性和最小轴长)相结合的多变量回归模型取得了最具临床意义的性能,其BAcc为0.78,MCC为0.6,与所需的95%敏感性相关。由此产生的DFS方面的分层是显著的(p = 0.00021),特别是与使用未经调和的原始数据相比(p = 0.17)。 

 

 原始和统一的BComBat的主成分分析。

本研究表明通过拟议的协调过程,来自对比增强CT的放射组学模型可以在两个中心的队列中得到训练和验证,并表现出了对II期和III期结直肠癌患者复发预测良好性能。这些模型可以协助临床对手术后的病人进行风险分层,并依次调整治疗方法,以达到患者利益的最大化。对于高复发风险的患者来说,可以进行术后监测或化疗的加强以巩固疗效

原文出处

Bogdan Badic,Ronrick Da-Ano,Karine Poirot,et al.Prediction of recurrence after surgery in colorectal cancer patients using radiomics from diagnostic contrast-enhanced computed tomography: a two-center study.DOI:10.1007/s00330-021-08104-4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1987066, encodeId=44d6198e0661d, content=<a href='/topic/show?id=a498422e7e6' target=_blank style='color:#2F92EE;'>#增强CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42277, encryptionId=a498422e7e6, topicName=增强CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun Jul 03 18:12:57 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729341, encodeId=a6931e2934103, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jan 23 02:12:57 CST 2023, time=2023-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453659, encodeId=7f2d145365929, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sat Feb 12 01:12:57 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991853, encodeId=6e8f1991853c9, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Tue Feb 22 03:12:57 CST 2022, time=2022-02-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1987066, encodeId=44d6198e0661d, content=<a href='/topic/show?id=a498422e7e6' target=_blank style='color:#2F92EE;'>#增强CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42277, encryptionId=a498422e7e6, topicName=增强CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun Jul 03 18:12:57 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729341, encodeId=a6931e2934103, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jan 23 02:12:57 CST 2023, time=2023-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453659, encodeId=7f2d145365929, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sat Feb 12 01:12:57 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991853, encodeId=6e8f1991853c9, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Tue Feb 22 03:12:57 CST 2022, time=2022-02-22, status=1, ipAttribution=)]
    2023-01-23 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1987066, encodeId=44d6198e0661d, content=<a href='/topic/show?id=a498422e7e6' target=_blank style='color:#2F92EE;'>#增强CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42277, encryptionId=a498422e7e6, topicName=增强CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun Jul 03 18:12:57 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729341, encodeId=a6931e2934103, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jan 23 02:12:57 CST 2023, time=2023-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453659, encodeId=7f2d145365929, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sat Feb 12 01:12:57 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991853, encodeId=6e8f1991853c9, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Tue Feb 22 03:12:57 CST 2022, time=2022-02-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1987066, encodeId=44d6198e0661d, content=<a href='/topic/show?id=a498422e7e6' target=_blank style='color:#2F92EE;'>#增强CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42277, encryptionId=a498422e7e6, topicName=增强CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun Jul 03 18:12:57 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729341, encodeId=a6931e2934103, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jan 23 02:12:57 CST 2023, time=2023-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453659, encodeId=7f2d145365929, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sat Feb 12 01:12:57 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991853, encodeId=6e8f1991853c9, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Tue Feb 22 03:12:57 CST 2022, time=2022-02-22, status=1, ipAttribution=)]

相关资讯

戒酒总是戒不动?这份全国性酒精所致癌症负担报告了解一下?

2018年酒精消费占阿根廷所有癌症死亡人数的2.3%,占所有癌症DALY的2.1%。大多数死亡和残疾调整生命年可归因于适度饮酒,因为酗酒者只占人口的一小部分。

Ta不仅摆平恼人的更年期,竟还大大降低女性胃肠道癌发病及死亡风险!真•妇女之友!

BMC Gastroenterol:更年期激素治疗对韩国胃肠道癌风险和死亡率的影响:基于人群的队列研究

超简单!这种厨房调料换一换,即可降低各种癌症风险达31%!

PLOS ONE:橄榄油摄入与癌症风险:系统回顾和荟萃分析。

Molecular Cell:刘颖研究组揭示氨基酸调控mTORC1信号通路活性新机制

研究人员设计了多肽类药物,并初步展现了良好的抑癌效应,将来有望成为治疗结直肠癌的新方法。

Cancer Discov:科学家识别出与结直肠癌发生相关的特殊细菌蛋白

与持续性细菌感染相关的慢性和低级别炎症或与结肠肿瘤的发生相关,然而,短暂性和自限性感染在细菌驱动的结肠肿瘤发生中的影响,研究人员尚不清楚。